This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Summit
March 18-20, 2025
Pre-Conference Workshops on March 17, 2025Sheraton Philadelphia Downtown | Philadelphia, PA

Alycia Shilton Lloyd
Executive Director, Hematology-Oncology, Patient Innovation & Engagement, Global Medical & Scientific Affairs at Merck


Alycia Shilton-Lloyd, PhD is the Executive Director, Hematology-Oncology, Patient Innovation & Engagement, at Merck. Alycia joined the team as part of the Merck integration of Imago BioSciences, a clinical stage biopharmaceutical company focused on developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), a rare blood cancer, and other bone marrow diseases.

In her role at Imago, Alycia held the position of Vice President of Medical Affairs and helped execute the Patient Focused Drug Development (PFDD) approach and provided crucial input into Imago's recent Phase 2 and 3 planning activities. Alycia led Imago’s patient engagement activities for bomedemstat, a novel LSD1 inhibitor and new once daily oral medication in late-stage clinical testing for Essential Thrombocythemia (ET), Myelofibrosis (MF) and Polycythemia Vera (PV). Alycia and her team developed a Diversity, Equity and Inclusion (DEI) approach for clinical study access that leveraged Imago’s core patient engagement strategy, as well as the six overreaching recommendations with the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) joint DEI Statement.

Prior to joining Imago, Alycia served as Executive Director, Medical Education and Strategic Planning at Gilead Sciences, where she led the global Strategic Planning, Patient Engagement, Learning & Development and Medical Education and Programs teams. At Gilead, Alycia started the first departmental chapter of Women at Gilead in 2017 and was named Women at Gilead Career Champion in 2019. Alycia received a Ph.D. in Molecular, Cellular and Developmental Biology, an M.S. in Biology, and a Masters in Philosophy from Yale University. Her research experience included identification of a novel interaction between hormone response and cell-adhesion pathways, and the coordination of three labs at Yale and Miami University (Ohio). Alycia also served as the Chief Scientific Officer of GeneEd, Inc, a 25 person early-stage company developing scientific e-Learning applications for pharmaceuticals and life sciences corporations. She has lectured at the university undergraduate level and served as an advisor and adjunct faculty member for the San Francisco State University Clinical Research Associate program.

Agenda Sessions

  • Innovating Rare Disease Clinical Trials – Boosting Inclusion and Achieving Commercial Success